All In Biotech

Investigational drug · Phase 2

Allogeneic umbilical cord mesenchymal stem cells

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction.

Phase 2

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

146

Any phase or sponsor naming "Allogeneic umbilical cord mesenchymal stem cells"

First trial start

2020

Aug 5, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Allogeneic umbilical cord mesenchymal stem cells", any sponsor or status.

Conditions studied

As listed on its trial records.

  • COVID-19 Infection
  • Multiple Sclerosis
  • ST Elevation Myocardial Infarction

Approved drugs for the same conditions: Coronary artery disease and heart attack · Multiple sclerosis · COVID-19 · Cardiovascular and metabolic · Neurology · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "Allogeneic umbilical cord mesenchymal stem cells" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for COVID-19 Infection

  • ibuzatrelvirPF-07817883Phase 32 trials

    Pfizer · COVID-19 SARS-CoV-2 Infection, COVID-19 Infection

  • COH04S1GEO-CM04S1, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1Phase 22 trials

    GeoVax, Inc. · COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.